 |
 |
|
|
|
| Tranexamic acid |
 |
| Tranexamic acid |
 |
| 1197-18-8 |
 |
Use: 1 of the prostate, urethra, lung, brain, uterus, adrenal, thyroid, liver and other rich plasminogen activator organ trauma or operation bleeding.
2 used as thrombolytic drugs, such as tissue plasminogen activator, streptokinase and urokinase (t-PA) antagonists.
3 artificial abortion, stillbirth and placenta early spalling, amniotic fluid embolism caused by fiber soluble hemorrhage.4 local fibrinolytic activity increased menorrhagia, anterior chamber hemorrhage and severe epistaxis.
5 is used to prevent or relieve the factor VIII or factor IX deficiency in patients with haemophilia bleeding after tooth extraction or oral operation.
6 central artery aneurysm rupture induced by a mild bleeding, such as subarachnoid hemorrhage and intracranial aneurysm hemorrhage, the product of hemostasis is superior to other antifibrinolytic drugs, but must pay attention to cerebral edema complicating or risk of cerebral infarction with.As for the intensive operation indications of patients, this product can only be used as auxiliary medicine.7 for the treatment of hereditary angioedema, which can reduce the number and severity of seizures.In 8 patients with hemophilia have active bleeding.
7 for the treatment of hereditary angioedema, which can reduce the number and severity of seizures.
In 8 patients with hemophilia have active bleeding.
|
 |
CAS£º1197-18-8
Molecular formula£ºC8H15NO2
MW£º157.21
Assay£º¡Ã98.0%
EC£º214-818-2
|
| Industrial field |
pharmaceutical |
|
|
 |
|
|
|
|
|
 |
| There are no existing companies to distribute selected chemical product |
|
 |
|
|
|
